InnoCyto - PE Human PD-L1 (CD274) Protein (C-His)

PE Human PD-L1 (CD274) Protein (C-His)

CHO cells transfected with either PD-L1 CAR or Mock plasmid were stained with PE conjugated PD-L1 His protein at 4ug_test

Cat #	Size	Price	Quantity
800801	25 ug	$245
800802	100 ug	$595

Bulk/Custom

Product Details

Application	Flow Cytometry
Format	Liquid, PE
Expression Host	HEK293
Target Name	PD-L1, CD274, B7-H1, PDCD1L1, PDCD1LG1,
Species	Human
Sources	Recombinant Human PD-L1 (Phe19-Thr239) with C-terminus His tag is expressed in CHO cells and conjugated to PE.
Accession Number	Q9NZQ7
Molecular Weight	The protein has a predicted molecular weight of 28kDa. Under DTT-reducing conditions, it migrates at approximately 35 kDa on SDS-PAGE prior to conjugation.
Affinity Tag	C-His
Regulatory Status	RUO
Formulation	1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein
Endotoxin level	Not tested
Protein Concentration	25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration.
Storage and Handling	Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2–8°C for up to six months.

Background Information

Programmed death-ligand 1 (PD-L1), also known as CD274 or B7-H1, is a transmembrane protein that plays a pivotal role in immune regulation by modulating T cell activity. PD-L1 is expressed on a wide range of cells, including antigen-presenting cells, epithelial cells, and many tumor cells. Its primary function is to bind to its receptor, programmed cell death protein 1 (PD-1), located on activated T cells. This interaction delivers an inhibitory signal that reduces T cell proliferation, cytokine production, and cytotoxicity, thereby maintaining immune homeostasis and preventing autoimmunity. However, in pathological contexts such as cancer, PD-L1 expression allows tumor cells to evade immune attack, creating an immunosuppressive microenvironment.

Structurally, PD-L1 is a type I transmembrane glycoprotein belonging to the B7 family of immune checkpoint molecules. The extracellular domain comprises two immunoglobulin-like regions—an IgV-like domain responsible for PD-1 binding and an IgC-like domain that stabilizes the molecule. The protein also contains a single transmembrane helix and a short cytoplasmic tail that lacks classical signaling motifs but may interact with intracellular partners influencing its stability and localization. The PD-L1–PD-1 complex adopts a well-characterized interface where the IgV domains of both molecules interact in a way that blocks T cell receptor-mediated activation signaling.

The main ligands of PD-L1 are PD-1 and CD80 (B7-1). While PD-1 engagement results in T cell inhibition, interaction with CD80 may yield bidirectional signaling effects depending on the cellular context. PD-L1 can be induced by inflammatory cytokines such as interferon-gamma (IFN-γ), linking innate immune responses to immune checkpoint modulation.

PD-L1 plays a major role in numerous diseases. Overexpression of PD-L1 is a hallmark of many cancers, including lung, melanoma, renal, and breast cancers, where it contributes to immune escape. Therapeutically, blocking the PD-1/PD-L1 axis with immune checkpoint inhibitors has revolutionized cancer treatment. Drugs such as pembrolizumab, nivolumab, and atezolizumab disrupt this inhibitory pathway, restoring antitumor T cell function. Moreover, PD-L1 is being explored as both a predictive biomarker for immunotherapy response and a target for novel therapies, including bispecific antibodies and CAR-T cells aimed at enhancing immune-mediated tumor clearance.

Have a product or application question? Consult our FAQs or contact us.

PE Human PD-L1 (CD274) Protein (C-His)

Product Details

Background Information

Data Sheets

Related Protocols

Related Products